Proposal for the classification of relapsed and refractory acute myeloid leukemias as the basis for an age-adjusted randomized comparison of sequentially applied high-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone (S-HAM).
Hiddemann
W
W
Department of Internal Medicine, University of Münster.
Aul
H C
HC
Maschmeyer
G
G
Urbanitz
D
D
Lathan
B
B
Reichle
A
A
Köppler
H
H
Donhuijsen-Ant
R
R
Ludwig
W D
WD
Grüneisen
T
T
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001317:Austria / Q000453:epidemiology; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage / Q000493:pharmacokinetics; D003630:Daunorubicin / Q000008:administration & dosage; D004351:Drug Resistance; D005860:Germany, West; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy* / Q000401:mortality; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D015337:Multicenter Studies as Topic; D009364:Neoplasm Recurrence, Local / Q000145:classification / Q000188:drug therapy*; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D013866:Thioguanine / Q000008:administration & dosage
D003561:Cytarabine; D008942:Mitoxantrone; D013866:Thioguanine; D003630:Daunorubicin